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Abstract
Background: In the development of borderline personality disorder (BPD) both genetic and environmental factors
have important roles. The characteristic affective disturbance and impulsive aggression are linked to imbalances in
the central serotonin system, and most of the genetic association studies focused on serotonergic candidate
genes. However, the efficacy of dopamine D2 receptor (DRD2) blocking antipsychotic drugs in BPD treatment also
suggests involvement of the dopamine system in the neurobiology of BPD.
Methods: In the present study we tested the dopamine dysfunction hypothesis of impulsive self- and other-
damaging behaviors: borderline and antisocial traits were assessed by Structured Clinical Interview for Diagnosis
(SCID) for DSM-IV in a community-based US sample of 99 young adults from low-to-moderate income families. For
the BPD trait analyses a second, independent group was used consisting of 136 Hungarian patients with bipolar or
major depressive disorder filling out self-report SCID-II Screen questionnaire. In the genetic association analyses the
previously indicated polymorphisms of the catechol-O-methyl-transferase (COMT Val158Met) and dopamine
transporter (DAT1 40 bp VNTR) were studied. In addition, candidate polymorphisms of the DRD2 and DRD4
dopamine receptor genes were selected from the impulsive behavior literature.
Results: The DRD2 TaqI B1-allele and A1-allele were associated with borderline traits in the young adult sample (p
= 0.001, and p = 0.005, respectively). Also, the DRD4 -616 CC genotype appeared as a risk factor (p = 0.02). With
severity of abuse accounted for in the model, genetic effects of the DRD2 and DRD4 polymorphisms were still
significant (DRD2 TaqIB: p = 0.001, DRD2 TaqIA: p = 0.008, DRD4 -616 C/G: p = 0.002). Only the DRD4 promoter
finding was replicated in the independent sample of psychiatric inpatients (p = 0.007). No association was found
with the COMT and DAT1 polymorphisms.
Conclusions: Our results of the two independent samples suggest a possible involvement of the DRD4 -616 C/G
promoter variant in the development of BPD traits. In addition, an association of the DRD2 genetic polymorphisms
with impulsive self-damaging behaviors was also demonstrated.
Background
Borderline personality disorder (BPD) is a severe mental
disorder with a high mortality rate as a result of suicide
and impulsive behavior [1]. The core symptoms include
emotional disturbance (affective instability, intense
anger, chronic feelings of emptiness), disturbed
cognition (identity disturbance, transient paranoid idea-
tion or dissociative symptoms), impulsivity (suicidal or
self-mutilating behavior, or other self-damaging beha-
viors, such as substance abuse, reckless driving, unsafe
sex, spending sprees, binge eating), and interpersonal
problems (intense unstable relationships, fear of aban-
donment). Interaction of multiple genetic factors and
distressing childhood experiences has been suggested in
the development of emotional dysregulation and
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family studies indicated substantial genetic underpin-
nings [2], and twin studies showed 42-69% heritability
estimates [3,4]. Animal and human studies have indi-
cated that reduced serotonin function and increased
norepinephrine activity in the brain lead to aggressive
and impulsive behavior [5]. Although several impulsive
behaviors (e.g. ADHD: Attention Deficit Hyperactivity
Disorder or substance abuse) have been linked to altered
dopamine function, involvement of the dopamine sys-
tem in BPD has been circumstantial. The main support-
ing evidence, thus far, comes from the therapeutic effect
of D2 receptor blocking antipsychotic drugs [6].
Hitherto, only a couple of workgroups have studied
dopamine system related polymorphisms in BPD. The
first genetic association study showing a dopaminergic
effect on BPD was conducted among depressed patients
[7]. The 9-repeat allele of the dopamine transporter
gene (DAT1, SLC6A3) showed significant association
with BPD, even when childhood abuse and neglect, and
borderline temperament were included in the analyses.
A recent study reported an over-representation of the
low activity Met/Met genotype of the catechol-O-
methyl-transferase (COMT) gene in 161 BPD patients
[8]. Since COMT metabolizes catecholamines, these
findings suggest that altered dopamine and/or norepi-
nephrine neurotransmission might be a contributing fac-
tor in the development of BPD. In spite of the
pharmacological evidence, dopamine D2 receptor
(DRD2) polymorphisms have not been studied in rela-
tion to BPD. Dopamine D4 receptor (DRD4) might be
another candidate, because of the preferential expression
of this D2-family member in the prefrontal cortex [9]
and its well-established role in ADHD [10] as well its
possible involvement in human personality traits of
novelty-seeking and impulsivity [11]. However, a pilot
study of 39 BPD patients did not show any significant
effect of DRD4 polymorphisms [12].
We aimed to investigate the possible involvement of
dopaminergic polymorphisms in the etiology of impul-
sive self- and other-damaging behaviors (assessed by
borderline and antisocial traits) in a previously studied
US community-based sample of 99 young adults from
low-to-moderate income families [13]. This group could
be regarded as an at-risk population, because it has
been shown that low family socioeconomic status con-
fers a risk for BPD [14] and low educational or occupa-
tional status is an important risk factor for suicide
attempts [15]. In this sample 4% were diagnosed with
BPD and 7% with antisocial personality disorder (APD)
in young adulthood, showing a prevalence 2-3 times
higher compared to the general community (BPD: 1-2%,
APD: 2-3%) [16,17]. A group of 136 Hungarian patients
with mood disorder served as the replication sample for
findings related to borderline traits, because borderline
diagnosis, as well as borderline traits, have a high preva-
lence rate among psychiatric inpatients (15%) [16].
In addition to the previously indicated dopaminergic
polymorphisms, namely the 40 bp VNTR (variable num-
ber of tandem repeats) of the DAT1 gene, and the
Val158Met polymorphism of the COMT gene, the most
commonly investigated DRD2 and DRD4 polymorph-
isms were genotyped. The DRD2 TaqIA polymorphism
was identified during the chromosomal localization of
the gene. However, this single nucleotide polymorphism
(SNP) is in the 3’ untranslated region, 10 kilobase down-
stream from the DRD2 gene, actually in the neighboring
ANKK1 gene [18]. Nevertheless, four independent work-
groups showed reduced D2 receptor density of the
minor A1-allele carriers [19-22], and only one reported
a negative finding [23]. Therefore, this polymorphism
might be a good marker for DRD2 density in the brain.
The DRD2 gene has been associated with alcoholism
and other addictive disorders [24], and is hypothesized
to be a reinforcement or reward gene. Recently, two stu-
dies showed an association between the DRD2/ANKK1
A1-allele and impulsive behavior among healthy young
adults [25,26]. To further assess the possible involve-
ment of the DRD2 gene, two additional SNPs (TaqIB
from intron 1 and TaqID from intron 2) were selected
for genotyping.
Within the DRD4 gene, the 48 bp VNTR in exon III
has received the most interest in psychiatric genetics
[10,11]. Recent studies suggested that the 7-repeat allele
of the DRD4 gene may result in reduced DRD4 expres-
sion, influencing RNA stability [27]. Therefore, other
polymorphisms located in the promoter region of the
DRD4 gene with predictable or proven effects on gene
expression might also be worthwhile to study. The -616
C/G and -521 C/T SNPs, anda1 2 0b pd u p l i c a t i o ni n
the 5’ untranslated region of the DRD4 gene have been
extensively studied in dopamine-related child psychiatric
disorders, such as ADHD [10]. Therefore, we have ana-
lyzed these four DRD4 gene variants in the two samples.
S i n c eg e n e×g e n ea n dg e n e×e n v i r o n m e n ti n t e r a c -
tions may be important in the development of psychia-
tric disorders, exploratory analyses investigating
previously reported interactions in the impulsive beha-
vior literature were also conducted. For example, DRD2
A1-allele × DRD4 7-repeat allele interaction has been
reported for impulsivity [25], sensation seeking [28], and
antisocial behavior [29], and DRD4 VNTR × DAT1
VNTR interaction has been reported for behavioral inhi-
bition [30]. Also, environmental risk and protective fac-
tors, such as maternal insensitivity or intervention
promoting positive parenting, were shown to interact
with the DRD4 7-repeat allele on child externalizing
(oppositional, aggressive) behavior [31,32].
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US sample of young adults
In the US sample 99 young adults from low-to-moder-
ate income families (59.6% female; age range 18-22)
participated in a study of adolescent-parent relation-
ships [13]. Forty one of the families had been partici-
pating in a longitudinal study of attachment
relationships since infancy, and were recruited at child
age 0-18 months. All 41 families were at or below fed-
eral poverty level at intake, and half of the families
were referred to clinical services during the young
adult’s infancy for concerns about the quality of care
provided (the other half were socioeconomically-
matched controls). An additional 48 crossectional
families were recruited as part of the young adult fol-
low-up study and matched to the longitudinal sample
on socioeconomic status. Hence, the combined study
sample of 99 young adults is regarded as an at-risk
sample (53.5% of the families had an income of
$40,000 per year or less; 43.4% of mothers had a high
school education or less; 37.4% were single parents).
The study was conducted in compliance with the Code
of Ethics of the World Medical Association and with
the requirements of the Hospital Institutional Review
Board and the National Institute of Mental Health. All
young adults and their mothers provided written
informed consent for their participation.
Ethnicity/race data was obtained from the mother of
the young adult during the interview by asking her to
classify the ethnicity and race of both herself and the
father (possible options for ethnicity: Hispanic or Latino;
Not Hispanic or Latino; possible alternatives for race:
American Indian or Alaska Native; Black or African
American; White; Asian; Native Hawaiian or other Paci-
fic Islander; more than one race). Of the 99 young
adults, 66 had two parents reported as White, 26 sub-
jects had one or two African American parents, and 7
subjects had one or two parents who were Hispanic.
The genetic analyses yielding significant association for
the total sample (N = 99) were repeated for the non-
Hispanic Caucasian subgroup (N = 66).
US sample symptom assessments
Young adult psychopathology was assessed using the
Structured Clinical Interview for Diagnosis (SCID) for
DSM-IV Axis I and II [33,34], which was administered
in the laboratory by trained clinicians (see clinical char-
acteristics for Axis I disorders in Table 1). Among the
99 young adults 2 were diagnosed with both BPD and
APD, 2 with BPD, 5 with APD, and 14 with other per-
sonality disorder(s). The pattern of antisocial or border-
line personality disorder traits among the young adults
were the following: 4% met criteria for a diagnosis of
BPD, however, 20% endorsed two or more borderline
symptoms; 7% of the sample met diagnosis of APD (i.e.
3 or more APD symptoms and 2 or more conduct dis-
order symptoms before age 15 years), and 26% showed
two or more antisocial symptoms. In the categorical
analyses (chi-square and binary logistic regression) bor-
derline and antisocial traits were coded as present if two
or more features of the disorder were endorsed.
In the analyses a severity of abuse variable was also
used: An overall rating for severity of abuse from birth
to age 18 was assigned by reviewing the Conflict Tactics
Scale second version [35], the Traumatic Stress Schedule
[36], and the Childhood Traumatic Experiences Scales-
Revised coded from one-hour semi-structured Adult
Attachment Interview [37], and any history of state pro-
tective services involvement. The severity of abuse scale
was coded as 0 - no occurrence of violence; 1 - harsh
punishment or witnessed violence; 2 - emotional/verbal
abuse; 3 - one type of physical or sexual abuse (using
state guidelines for abuse), or protective services/foster
care involvement; 4 - two or more forms of abuse/
trauma out of the three listed previously. Reliability of
the severity of abuse scale was assessed by having two
coders independently rate 37 of the 99 participants on
severity of abuse by reviewing the above set of assess-
ments; reliability between the two coders assessed by
intraclass correlation was high, ri = 0.99.
Hungarian patient sample
The independent replication sample consisted of psy-
chiatric inpatients diagnosed with mood disorders,
recruited from the Department of Psychiatry, Kútvölgyi
Clinical Centre (Budapest, Hungary) during their
depressive periods requiring treatment. Unrelated parti-
cipants of Caucasian (Hungarian) origin were included
in the present study, thus creating an ethnically homo-
genous population [38]. The study was conducted in
compliance with the Helsinki Declaration, and was
approved by the Local Ethical Committee (TUKEB), all
participants provided written informed consent. After
screening out organic causes of psychiatric disorders,
Table 1 Clinical characteristics in the US young adult
sample and in the Hungarian sample of depressive
patients
DSM-IV Axis I diagnoses US sample
N (%)
Hu sample
N( % )
Major Depression* 23 (23.2) 79 (58.1)
Bipolar Disorder 7 (7.1) 50 (36.8)
Schizophrenia 0 (0) 4 (2.9)
Schizoaffective Disorder 0 (0) 3 (2.2)
Anxiety Disorder 40 (40.4) 85 (62.5)
Substance Abuse 38 (38.4) 12 (8.8)
Psychotic symptoms 24 (24.2) 76 (55.9)
* including single episode
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clinical psychiatrist, the Axis I disorder frequencies are
presented in Table 1. Among the 136 patients (female
76.5%; mean age: 46.3 ± 10.5, age range: 21-64 years) 14
(10.3%) were diagnosed with personality disorders. For
the genetic analyses borderline symptoms were assessed
from the self-report SCID Screen questionnaire, which
showed good correlations with SCID-II interviews [40].
The number of BPD symptoms (0-9) was used as the
borderline scale; the internal consistency of the scale
was found to be satisfactory (Cronbach’s alpha: 0.729).
Genotyping and genotype grouping
Non-invasive DNA sampling was applied, and DNA was
isolated from buccal cells using the DNA-purification
kit obtained from Gentra (Minneapolis, US). Genotyping
procedures for the DRD2 TaqIA (rs1800497), TaqIB
(rs1079597), TaqID (rs1800498), and DAT1 40 bp
VNTR in the 3’ untranslated region were carried out
using published protocols [41-44]. Whereas VNTR gen-
otyping methods of the DRD4 48 bp VNTR in exon III
and 120 bp duplication in the promoter region, and the
allele-specific amplifications of the DRD4 -616 C/G
(rs747302), -521 C/T (rs1800955) and COMT Val158-
Met (rs4680) were developed and optimized in our
laboratory [45-47]. The genotyping accuracy was
checked by parallel genotyping of two independent
DNA samples per person, and by calculating chi-square
tests for deviation from the Hardy-Weinberg equili-
brium using Knud Christensen’s program [48]. Except
for the -616 C/G SNP in the Hungarian psychiatric sam-
ple, no significant deviations from the Hardy-Weinberg
equilibrium were detected in either populations. We
assume that the slight deviation from the equilibrium
(c
2 = 4.099, df = 1, p = 0.043) in the Hungarian patient
sample originates from possible association of the -616
C/G SNP with psychiatric disorder(s). In order to sup-
port this assumption, control subjects (with no psychia-
tric history) were recruited at the Institute of
Psychology, Eotvos Lorand University (N = 178, age:
23.2 ± 5.0; 72.5% female) and genotyped for the studied
dopaminergic polymorphism (see additional file 1). Our
data demonstrated that the non-clinical Hungarian sam-
ple was indeed in Hardy-Weinberg equilibrium for -616
C/G SNP (c
2 = 0.104, df = 1, p = 0.747).
In the genetic analyses the VNTRs were analyzed
according to the number of the risk allele, i.e. the DRD4
48 bp VNTR 7-repeat allele and the DAT1 40 bp VNTR
9-repeat allele (see Table 2 and 3). In the second set of
analyses the genotypes were grouped according to the
presence of the risk allele, resulting in DRD4 7-present
(7+) and 7-absent (7-) groups. At the DAT1 VNTR the
grouping was based on the presence of the 9-repeat
allele, resulting in 9-present (9+) and 9-absent (9-)
groups; the rare 3/10, 6/10, 10/11, and 10/12 genotype
were grouped together with the 10/10 genotype in the
9- group, whereas the rare 3/9 and 8/9 genotype were
regarded as having one 9-repeat allele, and grouped to
the 9+ group. At the SNP markers, homozygotes for the
minor allele were grouped together with heterozygotes
in the second round of analyses, i.e. DRD2 A1+ group
consisted of A1/A1 (TT) and A1/A2 (CT) genotypes,
DRD2 B+ group consisted of B1/B1 (AA) and B1/B2
(AG) genotypes. The DRD4 -521 C/T SNP was analyzed
in CC + CT vs. TT setting, and at the -616 C/G SNP
CC vs. CG + GG groups were compared.
Statistical analyses
The SPSS program for Windows (17.0 version) was used
for the statistical analyses. In the US young adult sample
Pearson chi-square analyses were conducted using the
symptom cut-off scores at 2 to assess the effect of dopa-
minergic polymorphisms. In the binary logistic regres-
sion analyses gender and severity of abuse were also
entered beside the dichotomous genetic variable in the
same step (block 1). In the exploratory interaction ana-
lyses of DRD4 48 bp VNTR, dichotomous genetic vari-
ables (DRD4 7+ vs 7-, DRD2 A1+ vs A1-, DAT1 9+ vs
9-), gender, and the 5-point scale of severity of abuse
were entered at block 1, whereas the created interaction
variable (DRD4 × DRD2, DRD4 × DAT1, or DRD4 ×
abuse) was entered in block 2. Genetic association ana-
lyses within the Hungarian clinical sample were con-
ducted by univariate analysis of variance using the
borderline scale as the dependent variable and the dopa-
minergic genotypes as the grouping factor, with sex and
age used as covariates. To control for multiple compari-
sons, the False Discovery Rate adjustment of significance
levels was used at a = 0.05 level [49].
Haplotype analyses were conducted by likelihood-
based association analysis using the Unphased program
[50], also direct molecular haplotyping was applied for
the DRD4 promoter -616 C/G and -521 C/T SNPs [46].
Linkage disequilibrium between the DRD2 SNPs was
calculated by the Haploview program [51] using the
Hungarian control sample genotype data: the DRD2
TaqIB SNP was in linkage with TaqIA (D’=0 . 9 4 7 ,L O D
=2 9 . 7 7 ,r
2 = 0.701) and with TaqID (D’=1 . 0 ,L O D=
12.17, r
2 = 0.212). Linkage disequilibrium for the DRD4
promoter polymorphisms has been previously reported
[46].
Results
Association analyses among at-risk US young adults
The previously indicated polymorphisms in the DAT1
and COMT gene were not associated with either bor-
derline or antisocial traits in the US young adult sample
(Table 2). However, both the DRD2 B1-allele and A1-
allele were significantly associated with borderline traits
(TaqIB 3 genotypes: c
2 = 14.935, df = 2, p = 0.001, B1+
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2 = 12.977, df = 1, p = 0.0003; TaqIA
3 genotypes: c
2 = 10.568, df = 2, p = 0.005, A1+ vs A1-
categories: c
2 = 9.477, df = 1, p = 0.002). These associa-
tions remained significant after correcting for multiple
comparisons (p < 0.0056). Subjects carrying at least one
B1-allele were six times more likely to develop border-
line symptoms, OR = 6.2 (2.15-17.85), whereas A1+ sub-
jects were five times more likely to have borderline
symptoms, OR = 5.17 (1.7-15.7). Similar results were
found in the Caucasian subgroup (N = 66): TaqIB 3
genotypes: c
2 = 15.415, df = 2, p = 0.0004; B1+ vs B1-
categories: c
2 = 14.139, df = 1, p = 0.0002, OR = 10.1
(2.7-37.6). TaqIA 3 genotypes: c
2 = 11.253, df = 2, p =
0.004; A1+ vs A1- categories: c
2 = 11.215, df = 1, p =
0.001, OR = 7.7 (2.13-27.99). With gender and severity
of abuse accounted for in the model, the effect of DRD2
SNPs was still significant (Table 4). Similar results
appeared in the Caucasian subgroup (Table 4). For the
Table 2 Genetic analyses of the dopaminergic polymorphisms in the US young adult sample
BPD trait (N = 99) APD trait (N = 98)
0 or 1 2 or more 0 or 1 2 or more
N (%) N (%) p N (%) N (%) p
COMT Met/Met 12 (15.2) 4 (20.0) 12 (16.7) 4 (15.4)
Met/Val 38 (48.1) 7 (35.0) 0.572 30 (41.7) 14 (53.8) 0.539
Val/Val 29 (36.7) 9 (45.0) 30 (41.7) 8 (30.8)
DAT1 9/9 9 (11.5) 1 (5.0) 8 (11.3) 2 (7.7)
40 bp one 9 25 (32.1) 7 (35.0) 0.689 25 (35.2) 7 (26.9) 0.576
VNTR no 9 44 (56.4) 12 (60.0) 38 (53.5) 17 (65.4)
DRD2 B1/B1 0 (0.0) 1 (5.0) 0 (0.0) 1 (3.8)
TaqIB B1/B2 15 (19.5) 11 (55.0) 0.001 17 (24.3) 9 (34.6) 0.137
B2/B2 62 (80.5) 8 (40.0) 53 (75.7) 16 (61.5)
B1+ 15 (19.5) 12 (60.0) 17 (24.3) 10 (38.5)
B1- 62 (80.5) 8 (40.0) 0.0003 53 (75.7) 16 (61.5) 0.170
TaqID C/C 22 (28.6) 5 (25.0) 21 (30.0) 6 (23.1)
C/T 32 (41.6) 12 (60.0) 0.276 27 (38.6) 17 (65.4) 0.046
T/T 23 (29.9) 3 (15.0) 22 (31.4) 3 (11.5)
TaqIA A1/A1 3 (3.8) 3 (15.0) 4 (5.6) 2 (7.7)
A1/A2 26 (32.9) 12 (60.0) 0.005 25 (34.7) 13 (50.0)
A2/A2 50 (63.3) 5 (25.0) 43 (59.7) 11 (42.3) 0.310
A1+ 29 (36.7) 15 (75.0) 29 (40.3) 15 (57.7)
A1- 50 (63.3) 5 (25.0) 0.002 43 (59.7) 11 (42.3) 0.126
DRD4 1/1 4 (5.1) 1 (5.0) 3 (4.2) 2 (7.7)
120 bp 1/2 26 (32.9) 9 (45.0) 0.592 26 (36.1) 9 (34.6) 0.782
dup 2/2 49 (62.0) 10 (50.0) 43 (59.7) 15 (57.7)
-616 C/C 14 (17.7) 9 (45.0) 14 (19.4) 9 (34.6)
C/G 41 (51.9) 9 (45.0) 0.020 39 (54.2) 11 (42.3) 0.289
G/G 24 (30.4) 2 (10.0) 19 (26.4) 6 (23.1)
C/C 14 (17.7) 9 (45.0) 14 (19.4) 9 (34.6)
C/G + G/G 65 (82.3) 11 (55.0) 0.010 58 (80.6) 17 (65.4) 0.118
-521 C/C 10 (12.7) 3 (15.0) 11 (15.3) 2 (7.7)
C/T 46 (58.2) 6 (30.0) 0.061 42 (58.3) 10 (38.5) 0.038
T/T 23 (29.1) 11 (55.0) 19 (26.4) 14 (53.8)
C/C + C/T 56 (70.9) 9 (45.0) 53 (73.6) 12 (46.2)
T/T 23 (29.1) 11 (55.0) 0.029 19 (26.4) 14 (53.8) 0.011
48 bp 7/7 2 (2.5) 2 (10.0) 3 (4.2) 1 (3.8)
VNTR one 7 20 (25.3) 5 (25.0) 0.314 17 (23.6) 8 (30.8) 0.773
no 7 57 (72.2) 13 (65.0) 52 (72.2) 17 (65.4)
The at-risk population of young adults was divided by the cut-off rate of 2 symptoms of borderline personality disorder (BPD) and 2 symptoms of antisocial
personality disorder (APD). For the VNTRs, genotype grouping was based on the number of DAT1 40 bp VNTR 9-repeat alleles and DRD4 48 bp VNTR 7-repeat
alleles. For the DAT1 VNTR, one DNA sample, for the DRD2 TaqIB and TaqID SNPs, two DNA samples did not give genotype result (total sample size therefore
was 98 or 97 in BPD and 97 or 96 in APD, respectively).
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inally significant association (p = 0.046) which did not
remain significant after correcting for multiple
comparisons.
Among the DRD4 polymorphisms, the -616 C/G and
-521 C/T promoter SNPs showed potentially interesting
associations with borderline and antisocial traits (Table
2). The -616 CC and -521 TT genotypes were overrepre-
sented among those who had 2 or more borderline or
antisocial symptoms. In the second round of analyses
homozygotes for the minor allele were grouped together
with heterozygotes. Using the CC vs CG + GG grouping
system at the -616 C/G SNP, the difference in genotype
distribution was nominally significant for borderline
symptoms (p = 0.010), whereas at the -521 C/T SNP the
CC + CT vs TT grouping showed nominally significant
results for both borderline (p = 0.029) and antisocial (p =
0.011) symptoms. In the Caucasian subgroup similar find-
ing emerged for the -616 C/G SNP when testing border-
line symptoms (c
2 = 6.732, df = 1, p = 0.009). Whereas
at the -521 C/T SNP the analyses showed only marginal
effect (borderline: c
2 = 3.609, df = 1, p = 0.057, antisocial:
c
2 = 3.493, df = 1, p = 0.062). Neither of the nominally
significant associations (p < 0.05) remained significant
after correcting for multiple comparisons (p < 0.0056).
However, in the logistic regression analyses (entering gen-
der and severity of abuse in the model), the -616 C/G
SNP had a significant effect on BPD symptoms at p <
0.0056 level (Table 4). Similar results emerged in the
Caucasian subgroup: severity of abuse and the number of
-616 C allele were significant predictors of BPD symp-
toms (p = 0.004, and p = 0.005, respectively, Table 4).
Table 3 Dopaminergic polymorphisms and borderline personality symptoms in the Hungarian patient sample
Genotype N BPD score ± STD F df p h
2 power
COMT Met/Met 34 4.79 ± 2.54 0.367 2,131 0.694 0.006 0.108
Met/Val 70 4.71 ± 2.29
Val/Val 32 5.16 ± 2.57
DAT1 9/9 11 4.64 ± 2.87 0.120 2,131 0.887 0.002 0.068
40 bp 9/10 48 4.75 ± 2.74 0.082 1,132 0.775 0.001 0.059
VNTR 10/10* 77 4.92 ± 2.13
DRD2 B1/B1 3 3.33 ± 3.22 1.712 2,131 0.184 0.025 0.355
TaqIB B1/B2 37 5.38 ± 2.31 1.518 1,132 0.220 0.011 0.231
B2/B2 96 4.68 ± 2.40
TaqID C/C 27 4.30 ± 2.54 1.490 2,131 0.229 0.022 0.313
C/T 59 5.31 ± 2.28
T/T 50 4.58 ± 2.43
TaqIA A1/A1 4 3.75 ± 2.75 0.460 2,131 0.632 0.007 0.124
A1/A2 41 4.90 ± 2.56 0.001 1,132 0.970 0 0.050
A2/A2 91 4.86 ± 2.34
DRD4 1/1 4 3.25 ± 2.06 1.611 2,131 0.204 0.024 0.336
120 bp 1/2 40 5.18 ± 2.18 1.604 1,132 0.208 0.012 0.242
dup 2/2 92 4.76 ± 2.50
-616 C/C 44 5.48 ± 2.45 5.146 2,131 0.007 0.073 0.818
C/G 56 4.80 ± 2.36 8.152 1,132 0.005 0.058 0.809
G/G 36 4.11 ± 2.27
-521 C/C 34 5.00 ± 2.54 0.463 2,131 0.630 0.007 0.124
C/T 65 4.62 ± 2.38 0.354 1,132 0.553 0.003 0.091
T/T 37 5.08 ± 2.37
48 bp 7/7 3 5.67 ± 1.53 0.282 2,131 0.754 0.004 0.094
VNTR one 7 35 4.77 ± 2.38 0.134 1,132 0.715 0.001 0.065
no 7 98 4.84 ± 2.45
Haplotype 0 68 4.40 ± 2.34 3.602 2,131 0.030 0.052 0.658
-616 C ~ 1 50 5.14 ± 2.46 6.969 1,132 0.009 0.050 0.746
-521 T 2 18 5.67 ± 2.30
The mean ± SD of the sum of borderline symptoms (BPD score) from the self-report SCID-II Screen questionnaire are presented for the different genotype
groups. Where it is indicated, in the second set of univariate ANOVAs rare homozygote genotypes (n < 5) or literature-based genotypes were grouped together
with the heterozygotes for the fixed factor; sex and age were used as covariates.
* At the DAT1 VNTR one 10/11 and one 10/12 sample were grouped together with the 10/10 (9-allele absent) genotype group.
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with either BPD or APD traits (Table 2).
Since dopaminergic polymorphisms have been asso-
ciated with alcohol and drug abuse, we checked for possi-
ble confounding genetic association with substance abuse
in our sample. Among the young adults 38.4% were diag-
nosed with substance abuse (Table 1). At the DRD2 SNPs
the association of the TaqIA polymorphism with sub-
stance abuse was marginally significant using the 3 geno-
type categories (c
2 = 5.34, df = 2, p = 0.069) and
nominally significant for the A1+ vs A1- categories (c
2 =
4.52, df = 1, p = 0.034), with 57.9% of the substance abuse
present group carrying the A1-allele vs 36.1% of the sub-
stance abuse absent group. Similar findings emerged at the
TaqIB 3 genotype categories: c
2 = 5.07, df = 2, p = 0.079,
and at the B1+ vs B1- categories: c
2 =4 . 2 1 ,d f=1 ,p=
0.04, with 39.5% of the substance abuse present group car-
rying the B1-allele vs 20.3% of the substance abuse absent
group. These results did not remain significant after
correcting for multiple testing. None of the DRD4 promo-
ter SNPs showed significant association with substance
abuse using either the 3 or 2 genotype categories.
Exploratory interaction analyses
According to previously reported findings, exploratory
interaction analyses were conducted with the DRD4 48
bp VNTR (for genotype grouping and analysis descrip-
tion see Methods section). The DRD4 7-repeat allele ×
severity of abuse interaction analysis did not yield a sig-
nificant result (p = 0.43). Nor did the DRD4 7+ × DRD2
A1+ interaction analysis result in a significant finding (p
= 0.725). There was a nominally significant finding at
the DRD4 7+ × DAT1 9+ interaction (p = 0.045), but
this result did not remain significant after correcting for
multiple testing.
Association analyses in the Hungarian inpatient
psychiatric sample
For confirmation of the findings regarding borderline
traits, univariate ANOVA was conducted in an
Table 4 Logistic regression analyses in the US young adult sample
Total sample (N = 99) Caucasians (N = 66)
OR (95% CI) p OR (95% CI) p
DRD2 TaqIB
gender 1.91 (0.61 - 5.97) 0.268 1.96 (0.47 - 8.20) 0.358
abuse 1.74 (1.15 - 2.61) 0.008 1.76 (1.08 - 2.89) 0.025
3 genetic groups 6.80 (2.14 - 21.57) 0.001 10.84 (2.56 - 45.90) 0.001
gender 1.97 (0.63 - 6.15) 0.241 2.05 (0.50 - 8.51) 0.322
abuse 1.76 (1.17 - 2.65) 0.006 1.80 (1.10 - 2.93) 0.018
2 genetic groups 7.00 (2.18 - 22.46) 0.001 11.20 (2.62 - 47.86) 0.001
DRD2/ANKK1 TaqIA
Gender 2.25 (0.75 - 6.76) 0.148 2.39 (0.62 - 9.22) 0.207
Abuse 1.59 (1.08 - 2.34) 0.019 1.59 (1.01 - 2.52) 0.048
3 genetic groups 3.27 (1.36 - 7.83) 0.008 3.70 (1.28 - 10.69) 0.016
Gender 2.25 (0.75 - 6.74) 0.147 2.71 (0.69 - 10.66) 0.154
Abuse 1.61 (1.10 - 2.37) 0.015 1.67 (1.05 - 2.65) 0.031
2 genetic groups 4.91 (1.54 - 15.64) 0.007 7.44 (1.91 - 28.98) 0.004
DRD4 -616 C/G
Gender 1.90 (0.60 - 6.01) 0.274 1.92 (0.46 - 8.00) 0.371
Abuse 2.12 (1.36 - 3.31) 0.001 2.16 (1.28 - 3.65) 0.004
3 genetic groups 4.64 (1.75 - 12.30) 0.002 5.40 (1.66 - 17.57) 0.005
Gender 1.64 (0.53 - 5.13) 0.392 1.85 (0.46 - 7.53) 0.390
abuse 2.06 (1.31 - 3.22) 0.002 2.04 (1.23 - 3.40) 0.006
2 genetic groups 7.65 (1.92 - 30.53) 0.004 7.98 (1.69 - 37.72) 0.009
DRD4 -521 C/T
gender 2.08 (0.70 - 6.12) 0.185 2.70 (0.73 - 9.95) 0.137
abuse 1.66 (1.14 - 2.43) 0.008 1.76 (1.12 - 2.78) 0.015
3 genetic groups 1.50 (0.63 - 3.56) 0.359 1.89 (0.66 - 5.38) 0.235
gender 1.92 (0.64 - 5.71) 0.244 2.82 (0.73 - 10.87) 0.131
abuse 1.70 (1.15 - 2.51) 0.008 1.85 (1.14 - 3.00) 0.013
2 genetic groups 2.67 (0.90 - 7.90) 0.077 3.50 (0.96 - 12.72) 0.057
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Screen questionnaire borderline scale in a Hungarian
sample of depressive patients (Table 3). Neither of the
DRD2 polymorphisms showed association with BPD
traits. On the other hand, the DRD4 -616 C/G SNP
showed similar association with BPD traits as observed
among the at-risk US young adults. The -616 CC geno-
type was associated with more severe borderline symp-
toms using the three genotype groups (p = 0.007).
Results were also significant for the combined CC vs
CG + GG genotype grouping (p = 0.005). Other dopa-
minergic polymorphisms did not show any significant
associations with the number of borderline symptoms in
this clinical sample.
Haplotype analyses
Since both the DRD2 TaqIB and TaqIA SNPs were
associated with BPD traits, haplotype analyses were con-
ducted using the Unphased program. Again, only the
US young adult sample analysis yielded significant
results (likelihood ratio c
2 = 12.49, df = 2, p = 0.002),
with the B1 ~ A1 (A ~ T) haplotype conferring risk for
BPD traits: OR = 4.89 (2.05 - 11.66). Furthermore, the
haplotype constructed from the three DRD2 SNPs was
also significantly associated with BPD traits: likelihood
ratio c
2 = 13.91, df = 4, p = 0.008, OR = 7.35 (2.38 -
22.7) for the A ~ C ~ T haplotype. The estimated hap-
lotype analyses for the DRD4 -616 C and -521 T alleles
showed association with BPD traits in both samples: US
young adult sample: likelihood ratio c
2 =1 0 . 4 1 ,d f=3 ,
p = 0.015; Hungarian patient sample: likelihood ratio c
2
= 9.81, df = 3, p = 0.02. In addition, the exact chromo-
somal localization of the two DRD4 SNPs could be
determined by direct haplotyping methods [46]. Genetic
association analyses were conducted using the number
of the -616C ~ -521T (C ~ T) haplotype. In the US
young adult sample the frequency of the DRD4 -616C ~
-521T haplotype was increased among those who had 2
or more borderline symptoms (55% had one C ~ T and
25% had two C ~ T haplotype vs 47.4% and 5.1%,
respectively, c
2 = 9.89, df = 2, p = 0.007). In the logistic
regression analyses, with gender and severity of abuse
accounted for in the model, the genetic effect was still
significant: OR = 4.76 (1.77 - 12.79), p = 0.002. In the
Hungarian patient sample univariate ANOVA showed a
similar effect: those who had -616C ~ -521T haplotype
on one or two chromosomes displayed a higher number
of borderline symptoms (for three groups: p = 0.03, for
two groups: p = 0.009, Table 3).
Discussion
Here we demonstrated a significant association between
the DRD4 -616 C/G promoter polymorphism and bor-
derline traits in two independent samples. Low-income
young adults as well as psychiatric patients carrying the
CC genotype displayed more borderline symptoms.
Moreover, the DRD4 promoter SNP combination of
-616C ~ -521T showed association with BPD traits in
both groups. Two DRD2 SNPs (TaqIA and TaqIB) were
also associated with borderline traits among at-risk
young adults, and the haplotype analyses confirmed the
role of the DRD2 gene. However, neither of the DRD2
polymorphisms had any significant effect in the sample
of psychiatric patients.
Since impulsive self-damaging behaviors constitute
one of the core features of BPD, our DRD2 findings
might support the association between the DRD2/
ANKK1 A1-allele and impulsive behavior reported in
healthy young adults [25,26]. Checking for the most fre-
quent symptoms in the studied groups indicated that
US young adults displaying two or more borderline
symptoms were indeed more likely to exhibit the two
forms of impulsivity, namely criterion 4 (impulsive self-
damaging behaviors, 75%) and criterion 5 (suicidal or
self-mutilating behavior, 50%). Another frequent symp-
tom in this group was intense and unstable relationships
(55%). Interestingly, the DRD2 genetic association
results can also be related to this phenotype, since pair
bonding in monogamous rodents is partially linked to
D2 receptors in nucleus accumbens and to the mesolim-
bic dopamine reward system [52]. Moreover, the A1-
allele has been associated with pair-bonding behaviors
in humans, as individuals with this low-expression
DRD2 allele were less likely to want to marry or have
children [28]. This observation is in agreement with ani-
mal studies where administration of a DRD2 antagonist
inhibited pair bond formation [reviewed in [53]].
On the other hand, depressive patients with borderline
features displayed more symptoms from the emotional
disturbance domain (chronic feelings of emptiness:
72.1%, affective instability: 67.6%, intense anger: 67.6%).
Also, paranoid ideation or dissociative symptoms were
quite frequent (68.4%) in this group. Based on the differ-
ences in BPD symptoms and in the genetic association
findings, we hypothesize that the DRD4 genetic associa-
tion (present in both samples) might indicate a dopami-
nergic vulnerability to BPD symptom development
involving the D4 dopamine receptor expressed preferen-
tially in the prefrontal cortex. Whereas the DRD2
genetic findings (present only among young adults) are
related more to the impulsive phenotype and/or to less
effective pair bonding, with an altered striatal D2 dopa-
mine receptor neurotransmission in the background.
The nominally significant effects of DRD2 polymorph-
isms on substance abuse in our sample might also relate
to the association between DRD2 and impulsive self-
damaging behaviors.
Limitations of the present study include the differ-
ences in the studied groups (community sample of
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ences in symptom assessments (SCID-II interview vs
self-report SCID-II Screen questionnaire). Another lim-
iting factor in the interpretation of our results is the
high rate of comorbid conditions, such as substance
abuse in the US young adult sample or anxiety disorder
in the Hungarian patient sample. Therefore, further ana-
lyses are required to assess the genetic effects on specific
BPD symptoms in a wide range of subjects, probably
involving healthy individuals without confounding
comorbid conditions.
We did not detect any significant association between
the investigated COMT or DAT1 polymorphisms and
borderline symptoms in either the US young adult sam-
ple or the Hungarian psychiatric patient population,
although the DAT1 9-repeat allele has been linked not
only to BPD [7] but also to impulsivity [54]. The latter
workgroup also showed higher reward-related ventral
striatum reactivity (which was associated with self-
reported impulsivity) in subjects with at least one DRD4
7-repeat allele and in DRD2 -141C Del carriers. They
argued for a connection between greater ventral stria-
tum reactivity and functional dopaminergic variants that
result in decreased postsynaptic dopamine receptor den-
sity. However, there is no clear-cut evidence concerning
the functionality of these dopaminergic polymorphisms.
The reduced DRD4 expression of the 7-repeat allele [27]
has not been replicated. The in vitro reporter gene
experiment of the DRD2 -141C Del allele showed lower
expression [55], whereas a SPECT study showed higher
striatal dopamine receptor density for the -141C Del
variant [21]. Finally, several studies indicated that the 40
bp VNTR in the DAT1 gene 3’ untranslated region
affects gene expression, but the results are controversial
concerning both the gene expression analyses [56,57]
and the SPECT studies [58-60].
A more recent report showed an association between
a reward-related impulsivity endophenotype in response
to a psychological stressor and the DRD2 C957T poly-
morphism among healthy adults [61]. Although the
findings of the in vitro and in vivo characterization of
this SNP were controversial [62,63], a follow-up PET
study indicated that the increased binding potential of
t h eT - a l l e l ew a sm o r ei m p o r t a n tt h a nt h es l i g h t l y
increased DRD2 density, making the DRD2 availability
of the T-allele higher compared to the C-allele [64]. To
date, only the reduced DRD2 density of the TaqI A1-
allele carriers has been convincingly replicated [19-22].
However, the DRD2/ANKK1 TaqIA polymorphism is
probably not directly involved in DRD2 gene expression.
The TaqIA SNP (rs1800497) is in linkage with TaqIB
SNP (rs1079597) and with C957T SNP (rs6277) within
the DRD2 gene, and these SNPs have also been
associated with altered DRD2 density [21,64]. In addi-
tion, the TaqIA SNP is in linkage with a couple of non-
synonymous SNPs of the ANKK1 gene [65]. Interest-
ingly, a neighboring non-synonymous SNP (rs273849,
Arg490His) of the ANKK1 gene has been recently
shown to alter NF-B function, which in turn may affect
DRD2 expression [66]. Therefore, the DRD2 TaqIA
polymorphism might still serve as a genetic marker in
psychogenetic studies, as indicated by meta-analyses of
alcohol and substance misuse [67,68].
Conclusions
Significant association was found between the DRD4
-616 CC genotype and BPD traits among US at-risk
young adults, which was replicated in a Hungarian psy-
chiatric patient sample. Association of the DRD2 TaqI
B1-allele and A1-allele was also observed among the US
young adults, however, this association was not present
in the Hungarian inpatient psychiatric sample. The asso-
ciation between the indicated dopaminergic SNPs and
BPD traits among young adults of low socioeconomic
status remained significant after controlling for variance
related to severity of abuse in the logistic regression
equation. The role of the COMT or DAT1 polymorph-
isms in BPD symptom development among at-risk
young adults or psychiatric patients was not supported
by the present association analysis. Our results highlight
the possible involvement of dopamine receptor variants
in the development of BPD traits and call for further
investigation of the dopamine system contribution in
BPD.
Additional file 1: Genotype and allele frequencies of dopaminergic
polymorphisms in the US and Hungarian groups. Genotype
frequencies are shown in the upper part, allele frequencies are shown in
the lower part of each dopaminergic polymorphism, namely the COMT
Val158Met, the DAT1 40 bp VNTR, the DRD2 TaqIB, TaqID, TaqIA SNPs,
and the DRD4 120 bp duplication, -616 C/G, -521 C/T, 48 bp VNTR.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1744-9081-6-4-
S1.DOC]
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